Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.37 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 2/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5018409 | 0.89 | S1PR1 (0.51) | S1PR1ROCK1GPR132 | |
| SCHEMBL5018432 | 0.86 | POLB (0.38) | S1PR1GPR132MMP12HDAC4MEF2D | |
| SCHEMBL5018357 | 0.85 | SMN1; SMN2 (0.39) | S1PR1ROCK1ROCK2MMP12 | |
| SCHEMBL5018131 | 0.82 | ROCK1 (0.58) | ROCK1ROCK2 | |
| SCHEMBL13991940 | 0.81 | CALCRL (0.43) | MMP12 | |
| SCHEMBL5018553 | 0.81 | LMNA (0.41) | MMP12 | |
| SCHEMBL5018434 | 0.80 | GPR132 (0.37) | S1PR1GPR132 | |
| SCHEMBL5018355 | 0.80 | METAP2 (0.40) | ROCK1ROCK2MMP12 | |
| SCHEMBL5018151 | 0.79 | LMNA (0.47) | ROCK1ROCK2 | |
| SCHEMBL5018149 | 0.79 | PLAU (0.48) | MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178490-B2 | Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178490-B2 | Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010054102-A2 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCB1, SLC47A1 | S1PR1 3764/4885ROCK1 3292/4885AAK1 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.